This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nordion Launches A New And Improved TheraSphere® Website To Meet The Needs Of Liver Cancer Physicians, Patients And Caregivers Worldwide

Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today that it has launched a new and improved, intuitive, feature-rich TheraSphere® website, providing liver cancer patients and physicians with customized TheraSphere® resources that include medical and clinical information, convenient online ordering, and innovative digital resources.

“The new website highlights the resources and programs that make TheraSphere® a truly unique treatment offering,” said Steve West, Nordion CEO and Chief Operating Officer, Targeted Therapies. “With physicians and patients increasingly seeking digital delivery of treatment information and resources, the new website is the global hub that connects our users to a complete suite of training and support, whether they’re administrating their first TheraSphere® dose or their 100th.”

Specifically for physicians, the site offers convenient online access to a suite of unique TheraSphere® resources, including:
  • TheraSphere® Preceptor Program: Connects physicians with experienced interventional radiologists that provide medical and technical advice to treatment users.
  • TheraSphere® Resource Center iPad App: A comprehensive educational tool designed for healthcare professionals, placing valuable product information at their fingertips.
  • Online Ordering for Standard and Custom Doses: TheraSphere® users can order product online or by email, phone or fax. This includes custom doses, which are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste.
  • Expanded clinical trial information: Up-to-date information on TheraSphere® Phase III clinical trials, which include YES-P (liver cancer patients with portal vein thrombosis) STOP-HCC (patients with hepatocellular carcinoma) and EPOCH (patients with colorectal cancer whose disease has metastasized to the liver).

In addition to the TheraSphere® animation video and comprehensive Patient Information Guide, liver cancer patients and caregivers around the world can now find product information in their language, on dedicated pages offering quick access to treatment centers and resources specific to their location.

The new website is optimized for mobile devices and all modern browsers, to meet the needs of users on the go, on their platform of choice.

Visitors can also follow @NordionInc on Twitter to keep up-to-date on TheraSphere® news and upcoming events, and can subscribe to the Nordion YouTube channel for the latest video content.

To learn more, visit the Nordion booth at the following interventional oncology industry events:

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs